Prexasertib
Tier C — Watch / tradePrexasertib
Targets：Checkpoint kinase 2, CHEK1
Indications (approved)：Head and neck squamous cell carcinoma, Endometrial cancer, 三阴性乳腺癌, 脑癌, 髓母细胞瘤, 中枢神经系统肿瘤, Myelodysplastic syndrome, Acute myeloid leukaemia
Regional status
Synthetic routes & intermediates2 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| PREXA-001 | 113305-94-5 | 5-aminopyrazine-2-carbonitrile |
| PREXA-002 | 1234015-62-3 | 1-(2-methoxy-6-((4-methoxybenzyl)oxy)phenyl)-3,3-bis(methylthio)prop-2-en-1-one |
| PREXA-003 | 1234015-67-8 | (E)-5-((3-(2-methoxy-6-((4-methoxybenzyl)oxy)phenyl)-1-(methylthio)-3-oxoprop-1-en-1-yl)amino)pyrazine-2-carbonitrile |
| PREXA-004 | 1234015-68-9 | 5-((5-(2-methoxy-6-((4-methoxybenzyl)oxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile |
| PREXA-005 | 1234015-69-0 | 5-((5-(2-hydroxy-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile |
| PREXA-006 | 58885-58-8 | tert-butyl (3-hydroxypropyl)carbamate |
| PREXA-007 | 1234015-66-7 | tert-butyl (3-(2-(3-((5-cyanopyrazin-2-yl)amino)-1H-pyrazol-5-yl)-3-methoxyphenoxy)propyl)carbamate |
| Code | CAS No. | Intermediate |
|---|---|---|
| PREXA-008 | 703-23-1 | 1-(2-hydroxy-6-methoxyphenyl)ethan-1-one |
| PREXA-009 | 1234015-61-2 | 1-(2-methoxy-6-((4-methoxybenzyl)oxy)phenyl)ethan-1-one |
| PREXA-010 | 59489-71-3 | 5-bromopyrazin-2-amine |
| PREXA-011 | 1234015-63-4 | 5-bromo-N-(5-(2-methoxy-6-((4-methoxybenzyl)oxy)phenyl)-1H-pyrazol-3-yl)pyrazin-2-amine |
| PREXA-012 | 1234015-64-5 | 2-(3-((5-bromopyrazin-2-yl)amino)-1H-pyrazol-5-yl)-3-methoxyphenol |
| PREXA-013 | 1234015-65-6 | tert-butyl (3-(2-(3-((5-bromopyrazin-2-yl)amino)-1H-pyrazol-5-yl)-3-methoxyphenoxy)propyl)carbamate |
Frequently asked questions
What are the approved indications of Prexasertib?
Approved indications include: Head and neck squamous cell carcinoma, Endometrial cancer, 三阴性乳腺癌, 脑癌, 髓母细胞瘤, 中枢神经系统肿瘤, Myelodysplastic syndrome, Acute myeloid leukaemia.
When does the Prexasertib patent expire?
No public expiry year is available for Prexasertib yet; this page updates once verified.
How many synthesis routes are recorded for Prexasertib?
2 synthesis routes are recorded; the shortest is 5 steps with 30 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Prexasertib intermediates?
All intermediates in Prexasertib routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Prexasertib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-11